High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease

Journal of Neuroscience

Volumn 27, Issue 9, 2007, Pages 2377-2386

  Oueslati, Abid ^a   Sgambato Faure, Véronique ^b,c   Melon, Christophe ^a   Kachidian, Philippe ^a   Gubellini, Paolo ^a   Amri, Mohammed ^d   Goff, Lydia Kerkerian Le ^a   Salin, Pascal ^a  

^a CNRS   (France)

^b INSERM   (France)

^c UNIV GRENOBLE ALPES   (France)

^d FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

Author keywords

Deep brain stimulation; Dyskinesias; FosB; GLT1; L DOPA; Motor cortex; Neuropeptides

Indexed keywords

BENSERAZIDE; CYTOCHROME C OXIDASE; LEVODOPA; MESSENGER RNA; OXIDOPAMINE; PREPRODYNORPHIN; PREPROENKEPHALIN; PREPROTACHYKININ; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FOSB; VESICULAR GLUTAMATE TRANSPORTER 1;

AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; CELL POPULATION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; DYSKINESIA; ELECTRODE; IMMUNOREACTIVITY; MALE; MOTOR CORTEX; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBTHALAMIC NUCLEUS; TREATMENT DURATION;

EID: 33847359555     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2949-06.2007     Document Type: Article

References (57)

1. Abosch A, Kapur S, Lang AE, Hussey D, Sime E, Miyasaki J, Houle S, Lozano AM (2003) Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery 53:1095-1102.
2. Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6:461-474.
3. Andersson M, Westin JE, Cenci MA (2003) Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 17:661-666.
4. Bacci JJ, Absi el H, Manrique C, Baunez C, Salin P, Kerkerian-Le Goff L (2004) Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. Eur J Neurosci 20:3331-3341.
5. Benabid AL, Krack PP, Benazzouz A, Limousin P, Koudsie A, Pollak P (2000) Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: methodologic aspects and clinical criteria. Neurology 55:S40-S44.
6. Boulet S, Lacombe E, Carcenac C, Feuerstein C, Sgambato-Faure V, Poupard A, Savasta M (2006) Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J Neurosci 8:10768-10776.
7. Bruet N, Windels F, Bertrand A, Feuerstein C, Poupard A, Savasta M (2001) High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. J Neuropathol Exp Neurol 60:15-24.
8. Bruet N, Windels F, Carcenac C, Feuerstein C, Bertrand A, Poupard A, Savasta M (2003) Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats. J Neuropathol Exp Neurol 62:1228-1240.
9. Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T, Bedard PJ (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47[4 Suppl 1]:S70-S78.
10. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2002) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61:186-196.
11. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14:404-416.
12. Carta AR, Pinna A, Cauli O, Morelli M (2002) Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 44:166-174.
13. Cenci MA (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23:105-109.
14. Cenci MA, Lee CS, Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706.
15. Chase TN, Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47:S122-S130.
16. Darbaky Y, Forni C, Amalric M, Baunez C (2003) High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task. Eur J Neurosci 18:951-956.
17. Degos B, Deniau JM, Thierry AM, Glowinski J, Pezard L, Maurice N (2005) Neuroleptic-induced catalepsy: electrophysiological mechanisms of functional recovery induced by high-frequency stimulation of the subthalamic nucleus. J Neurosci 25:7687-7696.
18. De Groot (1959) The rat forebrain in stereotaxic coordinates. AFD Natuurkunde N. V. Noord-Hallandsche Wetgevers Maatschappij. Amsterdam: Verhandelingen der Koninklijke Nederlandse Akademic van Wetenschappen.
19. Delfs JM, Ciaramitaro VM, Parry TJ, Chesselet MF (1995) Subthalamic nucleus lesions: widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J Neurosci 15:6562-6575.
20. Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C (2006) Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 69:805-812.
21. Follett KA (2004) Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurg Focus 17:E3.
22. Garcia L, D'Alessandro G, Bioulac B, Hammond C (2005) High-frequency stimulation in Parkinson's disease: more or less? Trends Neurosci 28:209-216.
23. Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26:2914-2922.
24. Gubellini P, Eusebio A, Oueslati A, Melon C, Kerkerian-Le Goff L, Salin P (2006) Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci 24:1802-1814.
25. Hajji MD, Salin P, Kerkerian-Le Goff L (1996) Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum. Eur J Neurosci 8:917-926.
26. Henry B, Crossman AR, Brotchie JM (1999) Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155:204-220.
27. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM (2003) Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol Oct 183:458-468.
28. Hilker R, Voges J, Ghaemi M, Lehrke R, Rudolf J, Koulousakis A, Herholz K, Wienhard K, Sturm V, Heiss WD (2003) Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord 18:41-48.
29. Kita H, Kitai ST (1987) Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 260:435-452.
30. Krack P, Fraix V, Mendes A, Benabid AL, Pollak P (2002) Postoperative management of subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 17 [Suppl 3]:S188-S197.
31. Lee KH, Blaha CD, Harris BT, Cooper S, Hitti FL, Leiter JC, Roberts DW, Kim U (2006) Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. Eur J Neurosci 23:1005-1014.
32. Lievens JC, Salin P, Nieoullon A, Kerkerian-Le Goff L (2001) Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. J Neurochem 79:893-902.
33. McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ (2004) DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res 132:146-154.
34. McIntyre CC, Savasta M, Kerkerian-Le Goff L, Vitek JL (2004) Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol 115:1239-1248.
35. Meissner W, Harnack D, Reese R, Paul G, Reum T, Ansorge M, Kusserow H, Winter C, Morgenstern R, Kupsch A (2003) High-frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. J Neurochem 85:601-609.
36. Nestler EJ, Kelz MB, Chen J (1999) DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Res 835:10-17.
37. Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T (2005) Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. J Neurosurg 103:968-973.
38. Olanow CW (2002) Surgical therapy for Parkinson's disease. Eur J Neurol 9 [Suppl 3]:31-39.
39. Orieux G, Francois C, Feger J, Hirsch EC (2002) Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. J Neurosci 22:8762-8770.
40. Oueslati A, Breysse N, Amalric M, Kerkerian-Le Goff L, Salin P (2005) Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur J Neurosci 22:2765-2774.
41. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. New York: Academic.
42. Perier C, Marin C, Bonastre M, Tolosa E, Hirsch EC (2002) AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. Eur J Neurosci 16:2236-2240.
43. Perier C, Marin C, Jimenez A, Bonastre M, Tolosa E, Hirsch EC (2003) Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats. J Neurochem 86:1328-1337.
44. Perlmutter JS, Mink JW (2006) Deep brain stimulation. Annu Rev Neurosci 29:229-257.
45. Perrotti LI, Hadeishi Y, Ulery PG, Barrot M, Monteggia L, Duman RS, Nestler EJ (2004) Induction of deltaFosB in reward-related brain structures after chronic stress. J Neurosci 24:10594-10602.
46. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.
47. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L (2004) Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 20:1255-1266.
48. Russmann H, Ghika J, Combrement P, Villemure JG, Bogousslavsky J, Burkhard PR, Vingerhoets FJ (2004) L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction. Neurology 63:153-155.
49. Salin P, Manrique C, Forni C, Kerkerian-Le Goff L (2002) High frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat. J Neurosci 22:5137-5148.
50. Schulte T, Brecht S, Herdegen T, Illert M, Mehdorn HM, Hamel W (2006) Induction of immediate early gene expression by high-frequency stimulation of the subthalamic nucleus in rats. Neuroscience 138:1377-1385.
51. Sgambato-Faure V, Buggia V, Gilbert F, Levesque D, Benabid AL, Berger F (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64:936-947.
52. Shi LH, Luo F, Woodward DJ, Chang JY (2006) Basal ganglia neural responses during behaviorally effective deep brain stimulation of the subthalamic nucleus in rats performing a treadmill locomotion test. Synapse 59:445-457.
53. Strafella AP, Sadikot AF, Dagher A (2003) Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease. NeuroReport 14:1287-1289.
54. Tai CH, Boraud T, Bezard E, Bioulac B, Gross C, Benazzouz A (2003) Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J 17:1820-1830.
55. Tel BC, Zeng BY, Cannizzaro C, Pearce RK, Rose S, Jenner P (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115:1047-1058.
56. Thobois S, Fraix V, Savasta M, Costes N, Pollak P, Mertens P, Koudsie A, Le Bars D, Benabid AL, Broussolle E (2003) Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease - a [11C]-raclopride PET study. J Neurol 250:1219-1223.
57. Zeng BY, Pearce RK, MacKenzie GM, Jenner P (2000) Alterations in pre-proenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12:1096-1104.